Efficacy and tolerability of nimesulide for the treatment of migraine attacks, a randomised, double blind, placebo controlled cross-over trial
Active, not recruiting
- Conditions
- migraine attacks with and without auraMedDRA version: 9.1Level: LLTClassification code 10027599Term: Migraine
- Registration Number
- EUCTR2005-000583-28-IT
- Lead Sponsor
- HELSINN HEALTHCARE SA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 162
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which nimesulide inhibits COX-2 to alleviate migraine attacks?
How does nimesulide compare to triptans in efficacy and tolerability for acute migraine treatment?
Are there specific biomarkers that predict response to nimesulide in migraine patients with aura versus without aura?
What are the potential adverse events associated with nimesulide use in migraine treatment and how are they managed?
What is the therapeutic potential of combining nimesulide with CGRP antagonists for migraine management compared to monotherapy?